Humabs BioMed, a subsidiary of Vir Biotechnology is a leading Swiss antibody therapeutics company that discovers and develops superior antibodies directly derived from individuals who have successfully overcome major diseases.
Vir and partner GSK are pleased to share that new preclinical live virus data support pseudovirus testing demonstrating that our investigational monoclonal antibody retains activity against all tested SARS-CoV-2 variants of concern, including Delta and Omicron.
Dr. Lanzavecchia worked for almost two decades at the Basel Institute for Immunology. He has been a professor at the University of Genova and at the Swiss Federal Institute of Technology, ETH Zurich.
Series of preclinical studies supports the Army’s pan-coronavirus vaccine development strategy
“The accelerating emergence of human coronaviruses throughout the past two decades and the rise of SARS-CoV-2 variants, including most recently Omicron, underscore the continued need for next-generation preemptive vaccines that confer broad protection against coronavirus diseases,” said Dr. Kayvon Modjarrad, Director of the Emerging Infectious Diseases Branch at WRAIR, co-inventor of the vaccine and the U.S. Army lead for SpFN. “Our strategy has been to develop a ‘pan-coronavirus’ vaccine technology that could potentially offer safe, effective and durable protection against multiple coronavirus strains and species.”
Market Data 
Markets 
AI
